3-苄基异恶唑-5-胺 | 119162-58-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-苄基异恶唑-5-胺
• 中文别名: 3-苄基-5-氨基异恶唑
• 英文名称: 3-benzylisoxazol-5-amine
• 英文别名: 3-Benzyl-1,2-oxazol-5-amine
• CAS: 119162-58-2
• 化学式: C₁₀H₁₀N₂O
• mdl: MFCD16301537
• 分子量: 174.202
• InChiKey: PJEXDUCPZGTNTP-UHFFFAOYSA-N

物化性质

• 熔点：
  127-129 °C
• 沸点：
  350.7±27.0 °C(Predicted)
• 密度：
  1.183±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  52
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-苄基异恶唑-5-胺 、 1-溴-3-苯基丙烷 在 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以51%的产率得到3-benzyl-N-(3-phenylpropyl)isoxazol-5-amine
  参考文献：
  名称：

  Identification of diphenylalkylisoxazol-5-amine scaffold as novel activator of cardiac myosin

  摘要：

  To identify novel potent cardiac myosin activator, a series of diphenylalkylisoxazol-5-amine compounds 4-7 have been synthesized and evaluated for cardiac myosin ATPase activation. Among the 37 compounds, 4a (CMA at 10 µM = 81.6%), 4w (CMA at 10 µM = 71.2%) and 6b (CMA at 10 µM = 67.4%) showed potent cardiac myosin activation at a single concentration of 10 µM. These results suggested that the introduction of the amino-isoxazole ring as a bioisostere for urea group is acceptable for the cardiac myosin activation. Additional structure-activity relationship (SAR) studies were conducted. Para substitution (-Cl, -OCH₃, -SO₂N(CH₃)₂) to the phenyl rings or replacement of a phenyl ring with a heterocycle (pyridine, piperidine and tetrahydropyran) appeared to attenuate cardiac myosin activation at 10 µM. Additional hydrogen bonding acceptor next to the amino group of the isoxazoles did not enhance the activity. The potent isoxazole compounds showed selectivity for cardiac myosin activation over skeletal and smooth muscle myosin, and therefore these potent and selective isoxazole compounds could be considered as a new series of cardiac myosin ATPase activators for the treatment of systolic heart failure.

  DOI：

  10.1016/j.bmc.2020.115742
• 作为产物：
  描述：

  苯乙酸甲酯 在 吡啶 、 盐酸羟胺 、 sodium hydride 作用下， 以 四氢呋喃 、 乙醇 、 mineral oil 为溶剂， 反应 106.17h， 生成 3-苄基异恶唑-5-胺
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE
  [FR] COMPOSÉS HÉTÉROCYCLIQUES CONTENANT UN COEUR PYRROLOPYRIDINE OU BENZIMIDAZOLE

  摘要：

  本发明涉及式(I)化合物及其药用盐，其中R1、R2、R3、R4、R5和n的定义如本文中所述。本发明还涉及包含这些化合物的药物组合物、使用这些化合物治疗各种疾病和失调的方法、制备这些化合物的方法以及在这些过程中有用的中间体。

  公开号：

  WO2011071725A1

文献信息

• In Situ Generated Magnesium Cyanide as an Efficient Reagent for Nucleophilic Cyanation of Nitrosoalkenes and Parent Nitronates
  作者：Pavel Yu. Ushakov、Andrey A. Tabolin、Sema L. Ioffe、Alexey Yu. Sukhorukov

  DOI：10.1002/ejoc.201801761

  日期：2019.3.7

  In situ generated magnesium cyanide is a convenient, readily available, non‐volatile and organic‐soluble reagent for hydrocyanation reactions. Efficient nucleophilic cyanation of π‐electrophiles such as nitronates, conjugated nitrosoalkenes, imines, α,β‐unsaturated ketones, methylenemalonates and azoalkenes was demonstrated.

  原位生成的氰化镁是用于氢氰化反应的便捷，易得，不挥发且有机可溶的试剂。证明了π-亲电子试剂（如硝酸盐，共轭亚硝基烯烃，亚胺，α，β-不饱和酮，亚甲基丙二酸酯和偶氮烯烃）的高效亲核氰化。
• HETEROCYCLIC COMPOUNDS CONTAINING A PYRROLOPYRIDINE OR BENZIMIDAZOLE CORE
  申请人：Boyer Stephen James

  公开号：US20130137680A1

  公开（公告）日：2013-05-30

  The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及公式（I）的化合物及其药学上可接受的盐，其中R1、R2、R3、R4、R5和n的定义如本文所述。本发明还涉及包含这些化合物的药物组合物，使用这些化合物治疗各种疾病和障碍的方法，制备这些化合物的过程以及用于这些过程的中间体。
• Heterocyclic compounds containing a pyrrolopyridine or benzimidazole core
  申请人：Boyer Stephen James

  公开号：US09073926B2

  公开（公告）日：2015-07-07

  The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5 and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本发明涉及式(I)化合物及其药学上可接受的盐，其中R1、R2、R3、R4、R5和n的定义如本文所述。本发明还涉及包含这些化合物的制药组合物、使用这些化合物治疗各种疾病和障碍的方法、制备这些化合物的过程以及在这些过程中有用的中间体。
• US9073926B2
  申请人：——

  公开号：US9073926B2

  公开（公告）日：2015-07-07